Levodopa response in early Parkinson's disease
Identifieur interne : 002234 ( Main/Exploration ); précédent : 002233; suivant : 002235Levodopa response in early Parkinson's disease
Auteurs : Robert A. Hauser [États-Unis] ; Peggy Auinger [États-Unis] ; David Oakes [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-12-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Clinical Trials as Topic, Databases, Factual (statistics & numerical data), Dose-Response Relationship, Drug, Female, Humans, Levodopa, Levodopa (therapeutic use), Male, Middle Aged, Multicenter Studies as Topic, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Placebo, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment, clinical response, levodopa, placebo, treatment.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Databases, Factual.
- Aged, Clinical Trials as Topic, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Retrospective Studies, Severity of Illness Index, Time Factors.
Abstract
To further characterize the short‐term levodopa response in early PD, we performed a retrospective analysis of the ELLDOPA study which randomized 361 early PD subjects to placebo, levodopa 150, 300, or 600 mg/day. We evaluated change in UPDRS motor scores (UPDRSm) from baseline to weeks 9 and 24, and identified changes in UPDRSm that best discriminated treatment with levodopa from placebo. Linear regressions were used to determine associations between baseline characteristics and changes in UPDRSm. Mean percent improvement in UPDRSm in levodopa‐treated subjects was greater than that for placebo‐treated subjects (27.4% vs. 5.8% at 9 weeks, P < 0.001 and 26.2% vs. 4.0% at 24 weeks, P < 0.001). UPDRSm change at 9 weeks ranged from –92.9% (improvement) to 85.7% (worsening) for levodopa and –86.7% to 160% for placebo, and at 24 weeks ranged from –100.0% to 242.9% for levodopa and –87.5% to 112.5% for placebo. UPDRSm improvements of 22.0% at 9 weeks and 23.8% at 24 weeks best discriminated treatment with levodopa 300 mg/day (a common initial maintenance dosage in clinical practice) from placebo. Significant associations were not observed between baseline subject characteristics and magnitude of response from baseline to week 24. We conclude that although levodopa treatment significantly improved PD signs when compared with placebo, there was a wide range and considerable overlap in clinical responses to levodopa and placebo. A substantial proportion of subjects with early PD did not experience a robust response to levodopa. An improvement in UPDRSm of ∼22% best discriminated levodopa treatment from placebo. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22759
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000466
- to stream Istex, to step Curation: 000466
- to stream Istex, to step Checkpoint: 000E36
- to stream PubMed, to step Corpus: 001A97
- to stream PubMed, to step Curation: 001A97
- to stream PubMed, to step Checkpoint: 001D41
- to stream Ncbi, to step Merge: 002886
- to stream Ncbi, to step Curation: 002886
- to stream Ncbi, to step Checkpoint: 002886
- to stream Main, to step Merge: 002A95
- to stream PascalFrancis, to step Corpus: 000C62
- to stream PascalFrancis, to step Curation: 002057
- to stream PascalFrancis, to step Checkpoint: 000E24
- to stream Main, to step Merge: 002F21
- to stream Main, to step Curation: 002234
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa response in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9F45EA68C8DD26C12497539861EEF4E613A6FD64</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22759</idno>
<idno type="url">https://api.istex.fr/document/9F45EA68C8DD26C12497539861EEF4E613A6FD64/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000466</idno>
<idno type="wicri:Area/Istex/Curation">000466</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E36</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:levodopa:response:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19908302</idno>
<idno type="wicri:Area/PubMed/Corpus">001A97</idno>
<idno type="wicri:Area/PubMed/Curation">001A97</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001D41</idno>
<idno type="wicri:Area/Ncbi/Merge">002886</idno>
<idno type="wicri:Area/Ncbi/Curation">002886</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002886</idno>
<idno type="wicri:Area/Main/Merge">002A95</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0071260</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C62</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002057</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000E24</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:levodopa:response:in</idno>
<idno type="wicri:Area/Main/Merge">002F21</idno>
<idno type="wicri:Area/Main/Curation">002234</idno>
<idno type="wicri:Area/Main/Exploration">002234</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa response in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-12-15">2009-12-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">16</biblScope>
<biblScope unit="page" from="2328">2328</biblScope>
<biblScope unit="page" to="2336">2336</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9F45EA68C8DD26C12497539861EEF4E613A6FD64</idno>
<idno type="DOI">10.1002/mds.22759</idno>
<idno type="ArticleID">MDS22759</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Databases, Factual (statistics & numerical data)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multicenter Studies as Topic</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Placebo</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>clinical response</term>
<term>levodopa</term>
<term>placebo</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Databases, Factual</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Clinical Trials as Topic</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multicenter Studies as Topic</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Placebo</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To further characterize the short‐term levodopa response in early PD, we performed a retrospective analysis of the ELLDOPA study which randomized 361 early PD subjects to placebo, levodopa 150, 300, or 600 mg/day. We evaluated change in UPDRS motor scores (UPDRSm) from baseline to weeks 9 and 24, and identified changes in UPDRSm that best discriminated treatment with levodopa from placebo. Linear regressions were used to determine associations between baseline characteristics and changes in UPDRSm. Mean percent improvement in UPDRSm in levodopa‐treated subjects was greater than that for placebo‐treated subjects (27.4% vs. 5.8% at 9 weeks, P < 0.001 and 26.2% vs. 4.0% at 24 weeks, P < 0.001). UPDRSm change at 9 weeks ranged from –92.9% (improvement) to 85.7% (worsening) for levodopa and –86.7% to 160% for placebo, and at 24 weeks ranged from –100.0% to 242.9% for levodopa and –87.5% to 112.5% for placebo. UPDRSm improvements of 22.0% at 9 weeks and 23.8% at 24 weeks best discriminated treatment with levodopa 300 mg/day (a common initial maintenance dosage in clinical practice) from placebo. Significant associations were not observed between baseline subject characteristics and magnitude of response from baseline to week 24. We conclude that although levodopa treatment significantly improved PD signs when compared with placebo, there was a wide range and considerable overlap in clinical responses to levodopa and placebo. A substantial proportion of subjects with early PD did not experience a robust response to levodopa. An improvement in UPDRSm of ∼22% best discriminated levodopa treatment from placebo. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>État de New York</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002234 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002234 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:9F45EA68C8DD26C12497539861EEF4E613A6FD64 |texte= Levodopa response in early Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |